Correlations of C-reactive Protein Levels and Erythrocyte Sedimentation Rates with Endoscopic Activity Indices in Patients with Ulcerative Colitis

2013 ◽  
Vol 59 (4) ◽  
pp. 829-837 ◽  
Author(s):  
Jin Young Yoon ◽  
Soo Jung Park ◽  
Sung Pil Hong ◽  
Tae Il Kim ◽  
Won Ho Kim ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Sedimentation Rates ◽  
C Reactive Protein ◽  
Protein Levels ◽  
Reactive Protein ◽  
Erythrocyte Sedimentation ◽  
Erythrocyte Sedimentation Rates ◽  
Activity Indices

scholarly journals Effect of Anti-Rheumatic Treatment on the Periodontal Condition of Rheumatoid Arthritis Patients

2021 ◽  
Vol 18 (5) ◽  
pp. 2529
Author(s):  
Menke J. de Smit ◽  
Johanna Westra ◽  
Marcel D. Posthumus ◽  
Gerald Springer ◽  
Arie Jan van Winkelhoff ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Sedimentation Rates ◽  
C Reactive Protein ◽  
Observation Study ◽  
Etanercept Treatment ◽  
Reactive Protein ◽  
Periodontal Condition ◽  
Erythrocyte Sedimentation ◽  
Erythrocyte Sedimentation Rates

Periodontitis, a bacterial-induced infection of the supporting soft and hard tissues of the teeth (the periodontium), is common in patients with rheumatoid arthritis (RA). As RA and periodontitis underlie common inflammatory pathways, targeting the progression of RA might mediate both periodontitis and RA. On the other hand, patients with RA on immunosuppressive medication have an increased risk of infection. Therefore, the objective of this longitudinal observation study was to assess the effect of methotrexate (MTX) and anti-tumor necrosis factor-α (anti-TNF, etanercept) treatment on the periodontal condition of RA patients. Overall, 14 dentate treatment-naive RA patients starting with MTX and 12 dentate RA patients starting with anti-TNF therapy in addition to MTX were included. Follow-up was scheduled matching the routine protocol for the respective treatments. Prior to the anti-rheumatic treatment with MTX or the anti-TNF therapy in addition to MTX, and during follow-up, i.e., 2 months for MTX, and 3 and 6 months for the anti-TNF therapy in addition to MTX, the periodontal inflamed surface area (PISA) was measured. The efficacy of the anti-rheumatic treatment was assessed by determining the change in RA disease activity (DAS28-ESR). Furthermore, the erythrocyte sedimentation rates were determined and the levels of C-reactive protein, IgM-rheumatoid factor, anti-cyclic citrullinated protein antibodies, and antibodies to the periodontal pathogen Porphyromonas gingivalis, were measured. Subgingival sampling and microbiological characterization of the subgingival microflora was done at baseline. MTX or anti-TNF treatment did not result in an improvement of the periodontal condition, while both treatments significantly improved DAS28 scores (both p < 0.01), and reduced C-reactive protein levels and erythrocyte sedimentation rates (both p < 0.05). It is concluded that anti-rheumatic treatment (MTX and anti-TNF) has negligible influence on the periodontal condition of RA patients.

scholarly journals Clinical Response and Complications are not Associated with Drug Levels in Patients with Severe Ulcerative Colitis on IV Cyclosporine Induction Therapy

2018 ◽  
Vol 24 (6) ◽  
pp. 1291-1297 ◽  
Author(s):  
Parita Patel ◽  
Andres Yarur ◽  
Sushila Dalal ◽  
Atsuhi Sakuraba ◽  
David T Rubin ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Postoperative Complications ◽  
Clinical Response ◽  
Induction Therapy ◽  
Kidney Injury ◽  
C Reactive Protein ◽  
Drug Levels ◽  
Protein Levels ◽  
Reactive Protein ◽  
Steroid Refractory

Abstract Background IV ciclosporin therapy is effective in steroid-refractory ulcerative colitis. The optimal drug level to achieve response and minimize complications during induction therapy is not known. Aim The primary aim was to evaluate if serum ciclosporin drug levels are associated with increased risk of colectomy within 90 days of hospitalization. Secondary aims were to determine if ciclosporin levels are associated with avoidance of colectomy at 7 and 30 days, if ciclosporin levels are associated with drug-related and postoperative complications, and if patient-specific factors are associated with response to ciclosporin. Methods We conducted a retrospective analysis of 81 hospitalized patients with steroid-refractory ulcerative colitis treated with ciclosporin. Risk factors for colectomy within 7, 30, and 90 days, medication-specific and postoperative complications were compared by first, mean, and peak ciclosporin level during IV induction therapy. Results There were 47 patients (58%) who underwent surgery. There were no differences between initial, mean, and peak ciclosporin levels among responders and nonresponders and treatment-related or postoperative complications. Responders within 90 days had lower C-reactive-protein levels (20mg/L vs. 38mg/L, P = 0.01), lower serum albumin concentrations (3.4g/dL vs. 3.7g/dL, P = 0.03), and higher rates of kidney injury (50% vs 17%, P = 0.002). Conclusion Initial, mean, and peak serum levels of ciclosporin did not correlate with response or toxicity. However, C-reactive-protein levels levels and kidney injury may be helpful in predicting clinical response to ciclosporin.

Sign in / Sign up

Export Citation Format

Share Document